Camp4 Therapeutics Corp

CAMP · Nasdaq · SIC 2834: Pharmaceutical Preparations
32
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTPase activating protein 1 (SYNGAP1)-related disorder, or SYNGAP1, a severe developmental...

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCAMPdiscussed_in_filing Artificial Intelligence
topic_mentionCAMPdiscussed_in_filing Cybersecurity
topic_mentionCAMPdiscussed_in_filing Trusted Computing
topic_mentionCAMPdiscussed_in_filing Blockchain & Crypto
topic_mentionCAMPdiscussed_in_filing Capital Expenditure
topic_mentionCAMPdiscussed_in_filing Regulation
topic_mentionCAMPdiscussed_in_filing Automotive
topic_mentionCAMPdiscussed_in_filing Healthcare & Bio
topic_mentionCAMPdiscussed_in_filing Platform & Ecosystem
topic_mentionCAMPdiscussed_in_filing Artificial Intelligence
topic_mentionCAMPdiscussed_in_filing Cybersecurity
topic_mentionCAMPdiscussed_in_filing Trusted Computing
topic_mentionCAMPdiscussed_in_filing Blockchain & Crypto
topic_mentionCAMPdiscussed_in_filing Capital Expenditure
topic_mentionCAMPdiscussed_in_filing Regulation
topic_mentionCAMPdiscussed_in_filing Automotive
topic_mentionCAMPdiscussed_in_filing Healthcare & Bio
topic_mentionCAMPdiscussed_in_filing Platform & Ecosystem
topic_mentionCAMPdiscussed_in_filing Artificial Intelligence
topic_mentionCAMPdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001736730-26-000016EDGAR101K words
2025-03-272024-12-310001736730-25-000022EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001736730-25-000094EDGAR23K words
2025-08-142025-06-300001736730-25-000070EDGAR—
2025-05-132025-03-310001736730-25-000039EDGAR—
2024-11-212024-09-300001410578-24-002045EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-240001736730-26-000021EDGAR1K words
2026-03-050001736730-26-000015EDGAR—
2026-01-090001736730-26-000004EDGAR—
2025-12-230001736730-25-000116EDGAR—
2025-12-180001628280-25-058009EDGAR—
2025-12-180001736730-25-000111EDGAR—
2025-11-060001736730-25-000092EDGAR—
2025-10-010001736730-25-000074EDGAR—
2025-09-100001736730-25-000072EDGAR—
2025-08-140001736730-25-000068EDGAR—

32 total filings indexed. 16 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001736730
TickerCAMP
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 98417e04d4e47864d31559d9627dd801188a6f29d2cb49b188343d61499ac789
parent: 0c5fdbf5f13a06723e7329c57b73c31ff6222955840c5c7aa34fa78dd0849166
content hash: f461df8128acc3b454e351f2218c8041ef74648fa37630ed8cf4756932777c7b
signed: 2026-04-13T04:44:11.344Z
sources: 6 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf